Bio-Techne Corporation (TECH)

Market Cap	7.55B -3.3%
Revenue (ttm)	1.21B +0.2%
Net Income	109.50M -16.8%
EPS	0.69 -16.3%
Shares Out	156.57M
PE Ratio	69.40
Forward PE	24.01
Dividend	$0.32 (0.66%)
Ex-Dividend Date	May 18, 2026

Volume	2,518,632
Open	47.30
Previous Close	47.37
Day's Range	47.11 - 48.27
52-Week Range	43.20 - 72.16
Beta	1.40
Analysts	Buy
Price Target	61.42 (+27.4%)
Earnings Date	May 6, 2026

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,100
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In fiscal year 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.

Analyst Summary

According to 15 analysts, the average rating for TECH stock is "Buy." The 12-month stock price target is $61.42, which is an increase of 27.40% from the latest price.

Price Target

$61.42

(27.40% upside)

Analyst Consensus: Buy